Skip To Main Content
Barrett H Childs on Muck Rack

Barrett H Childs

As seen in: The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barrett H

Contact Barrett H, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PI3K inhibitors in haematological malignancies

|
By Matthew J. Matasar, Florian Hiemeyer, Bayer AG, Barrett H Childs
| The Lancet Verified
We are writing in response to the Comment by Nicholas Richardson and colleagues1 from the US Food and Drug Administration, which discussed the use of PI3K inhibitors in haematological malignancies. As investigators who have treated many patients with PI3K inhibitors, beginning with the phase 1 study of idelalisib in 2010, we can attest to the transformative and life-saving nature of these therapies.
Open in Who Shared Issue with article?
See all 1 articles